BioScience Managers – Page 23 – BioScience Managers

Destiny Pharma announces research collaboration with the University of Southampton targeting infections in diabetic foot ulcers and cystic fibrosis

1st November 2018/in BioScience Managers

Brighton, United Kingdom – 1 November 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, that addresses the global problem of antimicrobial resistance (AMR), today announces it has been jointly awarded a National Biofilms Innovation Centre (NBIC) funded research collaboration with the University of Southampton. The […]

BioScience Managers appoints Dr. Kate Rowley as UK-based Investment Director

30th October 2018/in BioScience Managers

London, UK and Melbourne, Australia, 30 October 2018 – BioScience Managers Limited (BioScience Managers), the international healthcare investment firm today announces the appointment of Dr. Kate Rowley as Investment Director, based in London. Reflecting BioScience Managers’ international focus Dr. Rowley’s role will be to review and evaluate healthcare investment opportunities and manage investment deals from […]

Arecor successfully defends a key European patent in opposition proceedings on the subject of mitigation of aggregation of therapeutic proteins during storage

29th October 2018/in BioScience Managers

Cambridge, UK., 30th October 2018: Arecor Ltd (“the Company”), the UK-based leading formulation technology company, focussed on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides, continues to build a strong patent portfolio protecting the Company’s proprietary technology and product assets. Arecor is pleased to announce the successful outcome of the opposition proceedings […]

AVITA Medical Announces Commencement of Randomized Controlled Clinical Study of RECELL® System in Treatment of Children with Burn Injuries

25th October 2018/in BioScience Managers

Clinical study is being conducted in Brisbane, Australia in collaboration with the Queensland University of Technology and Lady Cilento Children’s Hospital Valencia, Calif., USA, and Melbourne, Australia, 25 October 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that the commencement of a randomized, controlled clinical study of the […]

Directorate Change

25th October 2018/in BioScience Managers

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) Directorate Change […]

UK government highlights global threat of AMR

24th October 2018/in BioScience Managers

Destiny Pharma plc (“Destiny Pharma” or the “Company”) Destiny Pharma’s lead asset, XF-73, well positioned to address the global threat of anti-microbial resistance highlighted in new UK government report Brighton, United Kingdom – 24 October 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address […]

BIA celebrates UK bioscience in creating innovative new drugs and treatment for patients

19th October 2018/in BioScience Managers

Destiny Pharma plc (“Destiny Pharma” or the “Company”) A series of videos and explainer documents launched, focusing on cutting-edge R&D taking place in UK biotech companies, including Destiny Pharma Destiny Pharma has been chosen to exemplify the UK’s leading status in antimicrobial resistance research Brighton, United Kingdom – 19 October 2018 – Destiny Pharma (AIM: DEST), […]

AVITA Medical Announces First U.S. Sales of RECELL® System and Commencement of Commercial Shipping Multiple U.S. burn centers incorporating RECELL System into their practices in advance of national U.S. market launch

17th October 2018/in BioScience Managers

Valencia, Calif., USA, and Melbourne, Australia, 18 October 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has received the first commercial sales orders from U.S. burn centers for the RECELL® Autologous Cell Harvesting Device (RECELL® System) and has commenced commercial shipment of the product. The U.S. […]

AmpliPhi Biosciences Announces Closing of Public Offering

16th October 2018/in BioScience Managers

Tuesday, October 16, 2018 4:10 pm EDT PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the closing of its previously announced underwritten public offering. Gross proceeds to AmpliPhi from […]

AVITA Medical Announces Medical Education Symposium and Presentation of RECELL® System Pivotal Trial Results at U.S. Midwest Region Burn Conference

15th October 2018/in BioScience Managers

Valencia, Calif., USA, and Melbourne, Australia, 15 October 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that a medical education symposium on the use of the RECELL® Autologous Cell Harvesting Device (RECELL® System) was held at the U.S. Midwest Region Burn Conference in Minneapolis. The symposium was led […]

Pages